Current Edition

Belzutifan

Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 …

Continue Reading →